Olaparib maintenance therapy does not have a significant detrimental effect on health-related quality of life in patients with relapsed ovarian cancer despite treatment-related adverse effects, an Australian-led clinical trial shows. In addition, patient-reported outcomes further support use of the poly(ADP-ribose) polymerase (PARP) inhibitor. The findings from the SOLO2 trial, randomising 196 patients to oral olaparib ...
Maintenance olaparib benefits extend to QOL in ovarian cancer
By Mardi Chapman
1 Aug 2018